Provided by Tiger Trade Technology Pte. Ltd.

NeuroPace Inc.

13.15
-0.6100-4.43%
Post-market: 13.150.00000.00%19:30 EDT
Volume:197.40K
Turnover:2.63M
Market Cap:448.33M
PE:-23.11
High:13.81
Open:13.81
Low:13.05
Close:13.76
52wk High:19.60
52wk Low:9.22
Shares:34.09M
Float Shares:23.28M
Volume Ratio:1.28
T/O Rate:0.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5690
EPS(LYR):-0.6560
ROE:-103.27%
ROA:-7.47%
PB:37.73
PE(LYR):-20.05

Loading ...

KeyBanc Initiates NeuroPace at Overweight With $18 Price Target

MT Newswires Live
·
Sep 18

Neuropace, Inc. : Keybanc Initiates Coverage with Overweight Rating and Target Price $18

THOMSON REUTERS
·
Sep 18

U.S. Research Roundup-Amrize, Carmax, VF Corp

Reuters
·
Sep 18

NeuroPace initiated with an Overweight at KeyBanc

TIPRANKS
·
Sep 18

Nippon Paper Industries to Temporarily Suspend Hungarian EV Battery Material Subsidiary

MT Newswires Live
·
Sep 07

NeuroPace to Present Fireside Chat at Cantor Global Healthcare Conference

Reuters
·
Sep 02

3 Stocks Estimated To Be Undervalued By Up To 37.3% Offering Potential Opportunities

Simply Wall St.
·
Aug 22

NeuroPace Forecasts 2026 Revenue USD 99.5 Million-101.5 Million

Reuters
·
Aug 12

NeuroPace, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

NeuroPace Rugi Bersih GAAP Q2 FY26 Menyempit 38,1% Jadi USD 6,2 Juta; Revenue Naik 17% Jadi USD 22,8 Juta

Reuters
·
Aug 12

NeuroPace, Inc. Q2 EPS Usd -0.18

Reuters
·
Aug 12

Neuropace, Inc. Q2 EPS Usd -0.18

THOMSON REUTERS
·
Aug 12

Press Release: NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

Dow Jones
·
Aug 12

NeuroPace, Inc. Expected to Post a Loss of 21 Cents a Share - Earnings Preview

Reuters
·
Aug 08

Analysts Conflicted on These Healthcare Names: Biogen (BIIB), NeuroPace (NPCE) and Gilead Sciences (GILD)

TIPRANKS
·
Jul 30

NeuroPace: FDA seeks additional clinical evidence from NAUTILUS trial

TIPRANKS
·
Jul 29

NeuroPace Price Target Maintained with a $20.00/Share by HC Wainwright & Co.

Dow Jones
·
Jul 29

NeuroPace faces FDA setback on epilepsy label expansion

TIPRANKS
·
Jul 29

NeuroPace Says FDA Deems Epilepsy Label Expansion Filing not Approvable in Current Form

Reuters
·
Jul 29

Neuropace - Receives FDA Notice Pma Supplement for Ige not Approvable in Current Form

THOMSON REUTERS
·
Jul 29